AstraZeneca

Q1 2024 Results

Fixed-income investor update

25 April 2024



Forward-looking statements

In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter 'the Group') provides the following cautionary statement: This document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, statements about expected revenues, margins, earnings per share or other financial or other measures. Although the Group believes its expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. The forward-looking statements reflect knowledge and information available at the date of preparation of this document and the Group undertakes no obligation to update these forward-looking statements. The Group identifies the forward-looking statements by using the words 'anticipates', 'believes', 'expects', 'intends' and similar expressions in such statements. Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond the Group's control, include, among other things: the ability of the Group and Fusion to complete the transactions contemplated by the arrangement agreement with Fusion, including the parties' ability to satisfy the conditions set forth in the arrangement agreement with Fusion; the ability of the Group and Amolyt Pharma to complete the transactions contemplated by the acquisition agreement with Amolyt Pharma, including the parties' ability to satisfy the conditions set forth in the acquisition agreement with Amolyt Pharma; the Group's statements about the expected timetable for completing the acquisitions of Fusion and Amolyt Pharma; the Group's and Fusion's beliefs and expectations and statements about the benefits sought to be achieved in the Group's pending acquisition of Fusion; the Group's and Amolyt Pharma's beliefs and expectations and statements about the benefits sought to be achieved in the Group's proposed acquisition of Amolyt Pharma; the potential effects of the acquisition of Fusion on both the Group and Fusion and of the acquisition of Amolyt Pharma on both the Group and Amolyt Pharma; the possibility of any termination of the arrangement agreement with Fusion or of the acquisition agreement with Amolyt Pharma; the expected benefits and success of "FPI-2265" (Ac225-PSMA I&T) and any combination product or eneboparatide ("AZP-3601") and any combination product; the possibility that any milestone related to any contingent value right may take longer to achieve than expected or may never be achieved and the resulting contingent milestone payment may never be realized; the effects of disruption from the transactions contemplated by the acquisition agreement with Amolyt Pharma and the impact of the announcement and pendency of the transactions on Amolyt Pharma's business; the effects of disruption from the transactions contemplated by the arrangement agreement with Fusion and the impact of the announcement and pendency of the transactions on Fusion's business; the risk that shareholder litigation in connection with the offer or the acquisition may result in significant costs of defense, indemnification and liability; the risk of failure or delay in delivery of pipeline or launch of new medicines the risk of failure to meet regulatory or ethical requirements for medicine development or approval; the risk of failures or delays in the quality or execution of the Group's commercial strategies; the risk of pricing, affordability, access and competitive pressures; the risk of failure to maintain supply of compliant, quality medicines; the risk of illegal trade in the Group's medicines; the impact of reliance on third-party goods and services; the risk of failure in information technology or cybersecurity; the risk of failure of critical processes; the risk of failure to collect and manage data in line with legal and regulatory requirements and strategic objectives; the risk of failure to attract, develop, engage and retain a diverse, talented and capable workforce; the risk of failure to meet regulatory or ethical expectations on environmental impact, including climate change; the risk of the safety and efficacy of marketed medicines being questioned; the risk of adverse outcome of litigation and/or governmental investigations; intellectual property-related risks to the Group's products; the risk of failure to achieve strategic plans or meet targets or expectations; the risk of failure in financial control or the occurrence of fraud; the risk of unexpected deterioration in the Group's financial position; the impact that global and/or geopolitical events may have or continue to have on these risks, on the Group's ability to continue to mitigate these risks, and on the Group's operations, financial results or financial condition. Nothing in this document, or any related presentation/webcast, should be construed as a profit forecast. There can be no guarantees that the conditions to the closing of the proposed transaction with Fusion will be satisfied on the expected timetable or at all or that "FPI-2265" (Ac225-PSMA I&T) or any combination product will receive the necessary regulatory approvals or prove to be commercially successful if approved. There can be no guarantees that the conditions to the closing of the proposed transaction with Amolyt Pharma will be satisfied on the expected timetable or at all or that eneboparatide ("AZP-3601") will receive the necessary regulatory approvals or prove to be commercially successful if approved.

Disclaimer

This presentation is neither an offer to sell nor a solicitation of an offer to buy any securities and shall not constitute an offer, solicitation, or sale in any jurisdiction in which an offer, solicitation, or sale is unlawful.

Non-GAAP measures

This presentation contains financial measures that are not calculated in accordance with generally accepted accounting principles (“GAAP”). These non-GAAP financial measures include net debt as well as our core financial measures and constant exchange rate (CER) growth rates. Non-GAAP measures included in this presentation should be considered in addition to, but not as substitutes for, the information we prepare in accordance with GAAP and as a result should be reviewed in conjunction with our financial statements. We provide reconciliations on slides 29 in the Appendix to this presentation between our non-GAAP financial measures and the respective most directly comparable financial measure calculated and presented in accordance with GAAP. However, the Company presents Core EPS guidance only at CER. It is unable to provide guidance on a Reported/GAAP basis because the Company cannot reliably forecast material elements of the Reported/GAAP result, including the fair value adjustments arising on acquisition-related liabilities, intangible asset impairment charges and legal settlement provisions.

Key messages

AstraZeneca Q1 2024 – Strong commercial performance and financial execution

Total revenue growth of 19%, core EPS growth of 13%

Maintaining innovation and pipeline delivery

Investing in new launches, near and mid-term pipeline

Investing in new platforms and technologies

Recent BD focused on capability building and enhancing therapy area leadership

Balanced and diversified company

By therapy area and geography

Financial execution – focus on operating margin expansion and cash flow

FY 2024 guidance reiterated

All growth rates at CER

Business update

Strong delivery in Q1 2024

Total Revenue growth

fueled by global Product Sales



Core EPS growth

despite substantial decrease in Other Operating Income[1]



2024 dividend: 7% increase to $3.10

All growth rates at CER. Due to rounding, the sum of a number or dollar values and percentages may not agree to totals. 1. $241 million dollar gain in the first quarter of 2023 following the divestment of Pulmicort Flexhaler in the US.
Appendix: Glossary.

Growth across therapy areas and geographies





Double-digit growth across therapy areas

Strong Emerging Markets performance, +26%

All growth rates at CER. Due to rounding, figures summed may not equal values and percentages may not agree to totals shown.

Q1 2024 pipeline events unlock significant growth potential

Unprecedented Phase III results

Phase III ADRIATIC trial

- *Imfinzi* potentially first IO therapy in LS-SCLC

Phase III LAURA trial

- Reinforcing *Tagrisso* as backbone TKI, moving into early-stage *EGFR*m NSCLC

2024 ASCO ANNUAL MEETING

Phase III ADRIATIC and LAURA trials selected for plenary

Transformative new approvals

***Tagrisso* + CTx**	***Enhertu***	***Ultomiris***
1L *EGFR*m NSCLC	Tumour agnostic	NMOSD

Continued investment in recent launches

WAINUA™ Truqap™ Voydeya® AIRSUPRA™

All growth rates at CER. Due to rounding, the sum of a number or dollar values and percentages may not agree to totals. Collaboration partners: Ionis (Wainua).

Appendix: Glossary.

Increasing momentum of high-value pipeline

Significant pipeline catalysts over the remainder of 2024

DESTINY-Breast06 *Enhertu*	2L HER2-low breast cancer	H1 2024
CAPItello-290 *Truqap*	Triple Negative Breast Cancer	H1 2024
CAPItello-281 *Truqap*	PTEN deficient mHSPC	H2 2024
TROPION-Breast02 Dato-DXd	Triple Negative Breast Cancer	H2 2024
WAYPOINT *Tezspire*	Chronic Rhinosinusitis with Nasal Polyps	H2 2024

Phase III trial initiations since FY2023

TROPION-Lung10 *Nonsq PDL1-high*	Dato-DXd ± rilvegostomig	**TROPION-Lung14**[1] *1L EGFRm NSCLC*	Dato-DXd ± *Tagrisso*
CLARITY-Gastric01 *2L+ Gastric*	AZD0901	**BalanceD-HF** *HF with renal imp*	balcinrenone / dapagliflozin FDC
ICAN *IgAN*	*Ultomiris*	**BaxDuo-Arctic** *CKD with HTN*	baxdrostat / dapagliflozin FDC
THARROS *COPD*	*Breztri*	**CHESTNUT** *HPP*	efzimfotase alfa

Pipeline enhanced with recent BD

Fusion Pharmaceuticals Inc. · AMOLYT PHARMA · ICOSAVAX · cellectis EDITING LIFE · GRACELL

1. First Subject In (FSI) anticipated in H1 2024, trial registered on clinicaltrials.gov. Fusion Pharmaceuticals and Amolyt Pharma acquisitions remains subject to customary external clearances. All clinical development plans mentioned herein subject to deal closure.

Appendix: Glossary

Oncology – Q1 2024

Total Revenue +26% with strong double-digit growth across all regions

Oncology

Q1 2024 $5.1bn, +26%



Q1 2024: key dynamics

- ***Tagrisso*** +15%, continued ADAURA and FLAURA demand, strong FLAURA2 awareness and early uptake in target patient segments
- ***Lynparza* PS** +11%, continued PARPi leadership
- ***Imfinzi*** +33%, achieved TOPAZ-1 (BTC) peak penetration in US, EU; JP repricing effective from February 1st
- ***Imjudo*** +70%, HIMALAYA (HCC) acceleration, durable POSEIDON (NSCLC) demand
- ***Calquence*** +35%, sustained BTKi leadership in 1L CLL
- ***Enhertu*** +79%, NPS growth in HER2+ (DB03), one-time EU pricing benefit, strong initial mBC uptake in Emerging Markets
- ***Truqap*** n/m, rapid adoption in core biomarker-altered population

---

- New indications: US (*Tagrisso* FLAURA2, *Enhertu* DPT02), JP (*Truqap* CAPItello-291)
- ASCO 2024 Plenaries: *Imfinzi* ADRIATIC, *Tagrisso* LAURA

All growth rates at CER.
Collaboration partners: Daiichi Sankyo (Enhertu), Merck & Co., Inc. (Lynparza).
Appendix: Glossary.

Oncology – R&D highlights

Fusion Pharmaceuticals acquisition expands next-gen Radioconjugate capabilities



30-50% of patients receive conventional radiotherapy[1]

Clinical-stage portfolio, combination potential with next-gen IO and DDR

Accelerates AstraZeneca's Radioconjugate research and manufacturing to commercial build

FPI-2265 in Prostate cancer

PSMA-Actinium RC with potential post-Pluvicto and Pluvicto-naïve

Maximum percent PSA change from baseline during the treatment period (weeks 0-28) by prior Lu treatment[2]



- PSA50 achieved in 43% of Lu-treated participants
- PSA50 achieved in 54% of Lu-naïve participants
- No discontinuations from Xerostomia

Multi-blockbuster opportunity in mCRPC with FPI-2265

1. KANTAR data, US 2025 estimates (across lung, head and neck, prostate, bladder, endometrial, ovarian, colon, rectal and gastric cancers) 2. TATCIST data presented at AACR 2024.
Fusion Pharmaceuticals acquisition remains subject to customary closing conditions; all clinical development plans mentioned herein subject to deal closure.
Appendix: Glossary.

BioPharmaceuticals – Q1 2024

Total Revenue $5.2bn, +16% – demand growth, accelerating new launch momentum

CVRM

Q1 2024 $3.1bn, +23%



Q1 dynamics

- ***Farxiga*** +45%, demand growth outpacing SGLT2i
- ***Lokelma*** +19%, K+ Binder leadership in US
- **roxadustat** +28%, demand growth

R&I

Q1 2024 $1.9bn, +17%



Q1 dynamics

- ***Fasenra*** +6%, continued IL-5 class leadership
- ***Breztri*** +54%, global market share gains
- ***Tezspire*** >2x, strong global launch demand

AIRSUPRA™

- **>18k unique prescribers[1]**
- **65k TRx in 1Q24[2]**

WAINUA™ (eplontersen) 45 mg injection for subcutaneous use

- **Strong initial ATTRv-PN launch uptake**

Beyfortus

- **90% effective in preventing infant hospitalization[3]**

All growth rates at CER.

1. IQVIA Xponent unique prescribers data, week ending 29 March 2. IQVIA NPA Data Monthly Ending 24 March. 3. Moline, Tannis, Toepfer et. al. Centres for Disease Control and Prevention, "Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus–Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season — New Vaccine Surveillance Network, October 2023–February 2024." March 2024. Collaboration partners: Amgen (Tezspire); Sanofi (Beyfortus).

Appendix: Glossary.

BioPharmaceuticals – R&D highlights

Exploratory endpoints support confidence in upcoming ATTR-CM opportunity



Phase III NEURO-TTRansform

Cardiomyopathic exploratory endpoints[1]



Exploratory data supports potential efficacy in ATTR-CM

CARDIO-TTRansform largest and only Phase III trial to incorporate cardiovascular mortality endpoints

Primary endpoint: composite of CV mortality and recurrent CV events

Secondary endpoint: change in 6MWT and KCCQ scores, rate of CV events, CV and all-cause mortality

Anticipate CARDIO-TTRansform trial readout 2025+

Collaboration partners: Ionis (Wainua).
Appendix: Glossary.

Rare Disease – Q1 2024

Total Revenue +16% in Q1 2024 driven by neurology

Rare Disease

Q1 2024 $2.1bn, +16%



Q1 2024: key dynamics

Sustainable, durable growth of C5 Franchise

- ***Ultomiris*** +34%, driven by demand growth in neurology indications (gMG, NMOSD)
- ***Soliris*** (8%), continued conversion to *Ultomiris*, partly offset by growth in Emerging Markets

Strensiq +21% and ***Koselugo*** +82%, driven by continued global demand and order timing in certain Emerging Markets

- New indications: US (*Ultomiris* NMOSD, *Voydeya* PNH-EVH), EU (*Voydeya* PNH-EVH)

All growth rates at CER.
1. Includes Kanuma and Koselugo.
Collaboration partners: Merck & Co., Inc. (Koselugo).
Appendix: Glossary.

Rare Disease – R&D

Blockbuster opportunity with proposed Amolyt Pharma acquisition



eneboparatide | Phase IIa hypoparathyroidism



Clinical priorities:

- Normalising serum calcium levels
- Decreasing urinary calcium excretion
- Preserving bone mineral density

Anticipated Phase III CALYPSO data in 2025

Potential best-in-class therapy with differentiated mechanism of action

Strong strategic fit, furthering commitment to rare endocrinology

Large unmet need:

US:	EU5:	JP:
106k	105k	42k

Amolyt Pharma acquisition remains subject to customary external clearances; all clinical development plans mentioned herein subject to deal closure.
Appendix: Glossary.

Financial update

Q1 2024 – Reported profit and loss



	Q1 2024 $m	CER change %	% Total Revenue
- Product Sales	*12,177*	*18*	*96*
- Alliance Revenue	*457*	*59*	*4*
- Collaboration Revenue	*45*	*66*	*-*
Total Revenue	**12,679**	**19**	**100**
Product Sales Gross Margin	81.8%	-	
Total operating expense[1]	(7,413)	10	58
- R&D expense	(2,783)	7	22
- SG&A expense	(4,495)	12	35
Other operating income and expense	67	(83)	1
Operating profit	3,115	31	25
Tax rate	22%		
Reported EPS	**$1.41**	**30**	

Due to rounding, the sum of a number of dollar values and percentages may not agree to totals.
Absolute values at actual exchange rates; changes at CER. Product Sales Gross Margin excludes the impact of Alliance and Collaboration Revenue and any associated costs, thereby reflecting the underlying performance of Product Sales. 1. Total operating expense includes distribution, R&D and SG&A expenses.
Appendix: Glossary.

Q1 2024 – Core profit and loss



	Q1 2024 $m	CER change %	% Total Revenue
- Product Sales	*12,177*	*18*	*96*
- Alliance Revenue	*457*	*59*	*4*
- Collaboration Revenue	*45*	*66*	*-*
Total Revenue	**12,679**	**19**	**100**
Product Sales Gross Margin	82.0%	-1pp	
Total operating expense[1]	(6,246)	15	49
- R&D expense	(2,698)	18	21
- SG&A expense	(3,413)	13	27
Other operating income and expense	65	(80)	1
Operating profit	4,310	15	34
Tax rate	21%		
Core EPS	**$2.06**	**13**	

Due to rounding, the sum of a number of dollar values and percentages may not agree to totals.
Absolute values at actual exchange rates; changes at CER. Product Sales Gross Margin excludes the impact of Alliance and Collaboration Revenue and any associated costs, thereby reflecting the underlying performance of Product Sales. 1. Total operating expense includes distribution, R&D and SG&A expenses.
Appendix: Glossary.

Net debt and FY guidance

Reiterating FY 2024 guidance

Net debt bridge



FY 2024 guidance reiterated (CER)

Total Revenue

- Low double-digit to low teens percentage increase

Core EPS

- Low double-digit to low teens percentage increase

Net debt/Adjusted EBITDA 1.9x

Anticipated FX impact: low single-digit adverse impact on Total Revenue and mid single-digit impact on Core EPS[3]

Due to rounding, the sum of a number of dollar values and percentages may not agree to totals. 1.Comprises disposal of intangible assets, movement in profit participation liability, purchase of intangible assets, payment of contingent consideration on business combinations, purchase and disposal of non-current asset investments, payment of Acerta Pharma share purchase liability and acquisitions of subsidiaries, net of cash acquired. The Company uses Debt issuance to finance new Business Development opportunities 2. Rolling 12m EBITDA adding back the impact of unwind of inventory fair value uplift recognised on acquisition of Alexion of $78m (FY 2023: $114m). AstraZeneca credit ratings: Moody's: short-term rating P-1, long-term rating A2, outlook stable. S&P Global Ratings: short-term rating A-1, long-term rating A, outlook stable. 3. If foreign exchange rates for April to December were to remain at the average rates seen in March 2024. Appendix: Glossary.

Net debt position

	31-Mar-24 $m	31-Dec-23 $m
Gross debt	(34,551)	(28,622)
Cash & cash equivalents	7,841	5,840
Other investments	180	122
Net derivative financial instruments	81	150
Closing net debt [1]	**(26,449)**	**(22,510)**

1. Net debt is a non-GAAP measure. The equivalent GAAP measure to Net debt is 'liabilities arising from financing activities', which excludes the amounts for cash and overdrafts, other investments and non-financing derivatives shown above and includes the Acerta Pharma share purchase liability of $nil (31 December 2023: $833m), which is shown in current other payables. Further details are available in our Q1 results announcement published on 25 March 2024.

Liquidity, debt and rating summary

- Strong liquidity at 31 March 2024:
  - Group cash and investments of $8bn
  - Undrawn $6.9bn committed bank facilities: $2bn mature in February 2025 and $4.9bn mature in April 2029

- Access to diverse sources of funding through US and European term debt and commercial paper programmes

Programme	Last Updated	Valid to	Limit	Rating (Moody's / S&P)	Utilisation as at 31/3/2024 [1]
SEC Shelf Registration Statement	Mar-24	Mar-27	Unlimited	A2 / A	USD 25.1bn
Euro Medium Term Note Programme	Jun-23	Jun-24	USD 10bn	A2 / A	USD 4.8bn
US Commercial Paper	N/A	N/A	USD 15bn	A-1 / P-1	USD 1.0bn
Euro-Commercial Paper	May-20	N/A	EUR 10bn	Issuer rating	None

[1] Notional bond values. FX converted at 31 March 2024 spot rates (USD/EUR 0.927; USD/GBP 0.793)

- The Board continues to target a strong, investment-grade credit rating

- The Company is currently rated as:
  - Moody's: A2 Stable outlook / P1
  - Standard & Poor's: A Stable outlook / A1

Smooth debt maturity profile with seven-year average life

Debt Maturity Profile at 31 March 2024 [1]



1. Notional bond values. FX converted at 31 March 2024 spot rates (USD/EUR 0.927; USD/GBP 0.793). Current portion of leases of $281m are included in 2024, whilst non-current leases of $961m have been excluded from the chart.

Appendix & Glossary

- Glossary
- ESG – summary of sustainability progress
- Oncology tumour maps
- Reported to Core reconciliation
- Treasury policy



Glossary – abbreviations

1L	=	First-line or Front-line
2L	=	Second-line
6MWT	=	6-minute walk test
ADsCa	=	Albumin-adjusted serum calcium
ASCO	=	American society of clinical oncology
ATTR-CM	=	Transthyretin amyloid cardiomyopathy
ATTR-PN	=	Transthyretin amyloid polyneuropathy
BTC	=	Biliary tract cancer
BTKi	=	Bruton's tyrosine kinase
C5	=	Complement component 5
Capex	=	Capital expenditure
CER	=	Constant exchange rates
CFO	=	Cash flow from operations
CKD	=	Chronic kidney disease
CLL	=	Chronic lymphocytic leukemia
CLDN18.2	=	Claudin 18 isoform 2
cm	=	Centimeter
COPD	=	Chronic obstructive pulmonary disease
CTx	=	Chemotherapy
CV	=	Cardiovascular
CVRM	=	Cardiovascular, renal and metabolism
DDR	=	DNA damage response
EBITDA	=	Earnings before interest, tax, depreciation and amortisation
*EGFR*m	=	Epidermal growth factor receptor mutation
EPS	=	Earnings per share
ERoW	=	Established rest of world
EU	=	Europe
FDC	=	Fixed dose combination
FX	=	Foreign exchange
gMG	=	Generalised myasthenia gravis
HCC	=	Hepatocellular carcinoma
HF	=	Heart Failure
HLR	=	High-level results
hMPV/RSV	=	Human metapneumovirus/respiratory syncytial virus
HPP	=	Hypophosphatasia
HtN	=	Hypertension
IgAN	=	Immunoglobulin A Nephropathy
IL5	=	Interleukin 5
IO	=	Immuno-oncology
JP	=	Japan
K+	=	Potassium
KCCQ	=	Kansas City Cardiomyopathy Questionnaire
LS-SCLC	=	Limited stage small-cell lung cancer
LV	=	Left ventricular
mBC	=	Metastatic breast cancer
mg/dL	=	Miligrams per decilitre
mCRPC	=	Metastatic castration-resistant prostate cancer
mHSPC	=	Metastatic hormone sensitive prostate cancer
mL	=	Milliliter
n/m	=	Not material
NMOSD	=	Neuromyelitis optica spectrum disorder
Nonsq	=	Non-squamous
NSCLC	=	Non-small cell lung cancer
NT-proBNP	=	N-terminal pro-B-type natriuretic peptide
PARPi	=	Poly-ADP ribose polymerase inhibitor
PDL1	=	Programmed cell death ligand 1
PNH-EVH	=	Paroxysmal nocturnal hemoglobinuria with extravascular haemolysis
PSA	=	Prostate-specific antigen
PSA50	=	Prostate-specific antigen 50
PTEN	=	Phosphatase and TENsin homolog deleted on chromosome 10
R&I	=	Respiratory and immunology
RC	=	Radioconjugates
Renal imp	=	Renal impairment
SGLT2i	=	Sodium/glucose cotransporter 2 inhibitor
Stg. III u/r NSCLC	=	Stage III unresectable non-small cell lung cancer
TKI	=	Tyrosine kinase inhibitor
ULN	=	Upper limit of normal
V&I	=	Vaccines and immune therapies

2023 Sustainability highlights

Progress on our overall strategy includes:

15
public and private sector organisations convened by AstraZeneca CEO through the Sustainable Markets Initiative to accelerate transition to net-zero health systems

87%
of employee survey respondents say that they understand their contributions to our sustainability priorities

25/27
of sustainability targets in Sustainability Data Annex are **"on plan"**

Access to Healthcare

127,384
healthcare workers and others trained[1] (cumulative)
By 2025: 170,000

>66.4m
people reached through Access to Healthcare programmes (cumulative)[1]
By 2025: 50m

>13.6m
people reached through our patient assistance programmes (cumulative)

Environmental Protection

67.6%
reduction in Scope 1 and Scope 2 greenhouse gas emissions
By 2026: 98% from 2015 base year

19.5%
reduction in our water use
By 2025: 20% below 2015 baseline

13.2%
reduction in our waste
By 2025: 10% below 2015 baseline

Ethics and Transparency

50.1%
senior middle management roles held by women
By 2025: reach gender equality in management positions

11 countries
with supplier diversity programmes
By 2025: 10 new countries outside of the US

83%
of employee survey respondents feel we have a "speak up" culture

1. From our philanthropic programmes including; Healthy Heart Africa and Young Health Programme.

AstraZeneca in Lung Cancer

Ambition for >50% of lung cancer patients to be eligible for AZN medicine by 2030

	resectable	unresectable		metastatic	
	Stg. I-III	Stg. I-II	Stg. III	1L	2L+
Est. epi (G7)	~200K	~30K	~70K	~350K	~290K
IO sensitive c.70%	*Imfinzi* **AEGEAN** volrustomig + CTx **NEOCOAST-2**	*Imfinzi* w/ SBRT **PACIFIC-4**	CRT → *Imfinzi* **PACIFIC** CRT + *Imfinzi* **PACIFIC-2** *Imfinzi* combos **PACIFIC-8, -9** improvements across PD-L1 spectrum	*Imfinzi* + *Imjudo* + CTx **POSEIDON** Dato-DXd + IO **TROPION-Lung08/TROPION-Lung07/AVANZAR** *Enhertu* + IO + CTx **DESTINY-Lung03** volrustomig + CTx **eVOLVE-Lung02** rilvegostomig (PD1/TIGIT) **ARTEMIDE-1**	*Imfinzi* + ceralasertib **LATIFY** Dato-DXd **TROPION-Lung01** AZD9592 (EGFR/cMET ADC) **EGRET** sabestomig (PD1/TIM3)
*EGFR*m c.16%	*Tagrisso* **ADAURA** *Tagrisso* **neoADAURA**		CRT → *Tagrisso* **LAURA**	*Tagrisso* **FLAURA** *Tagrisso* + CTx **FLAURA2**	savolitinib + *Tagrisso* **SAFFRON/SAVANNAH** AZD9592 (EGFR/cMET ADC) **EGRET** Dato-DXd **TROPION-Lung01** **TROPION-Lung05**
Other tumour drivers c.12%			CRT → *Imfinzi* **PACIFIC**		
*HER2*m c.2%				*Enhertu* **DESTINY-Lung04**	*Enhertu* **DESTINY-Lung02**

established SoC

Leading the future of lung cancer treatment

- Establishing *Tagrisso* as backbone TKI in *EGFR*m
- *Imfinzi* leading IO in unresectable
- Advancing best-in-class ADCs to replace systemic chemotherapy
- Delivering next-wave bispecifics to improve on PD1/PD-L1
- Developing novel combinations, including IO + ADCs
- Investing behind new technologies and platforms, including cell therapy and testing/screening

Collaboration partners: Daiichi Sankyo (Enhertu, Dato-DXd), Compugen (rilvegostomig).
Appendix: Glossary.

AstraZeneca in Breast Cancer

Ambition to eliminate breast cancer as a cause of death



All numbers are approximate. Illustrative settings and populations, not to scale.
Collaboration partners: Daiichi Sankyo (Enhertu, Dato-DXd), Merck & Co., Inc. (Lynparza).
Appendix: Glossary.

AstraZeneca in Breast Cancer

Ambition to eliminate breast cancer as a cause of death



All numbers are approximate. Illustrative settings and populations, not to scale.
Collaboration partners: Daiichi Sankyo (Enhertu, Dato-DXd).
Appendix: Glossary.

Q1 2024 Reconciliation of Reported to Core Financial Measures

	Reported $m	Restructuring $m	Intangible Asset Amortisation & Impairments $m	Other[1] $m	Core[2] $m
Gross Profit	10,461	20	10	-	10,491
Distribution Expense	(135)	-	-	-	(135)
R&D Expense	(2,783)	80	4	1	(2,698)
SG&A Expense	(4,495)	97	941	44	(3,413)
Other Operating Income & Expense	67	(2)	-	-	65
Operating Profit	3,115	195	955	45	4,310
Net Finance Expense	(302)	-	-	57	(245)
Taxation	(620)	(45)	(183)	(19)	(867)
Earnings Per Share	$1.41	$0.10	$0.50	$0.05	$2.06

1. Further details are available in our Q1 results announcement published on 25 March 2024.
2. Each of the measures in the Core column in the above table are non-GAAP financial measures.

Prudent treasury risk-management policies

The Company operates with a centralised Treasury structure so that key Treasury risks are managed at a Group level.

Liquidity Policy
- Prudent level of available cash and unutilised credit facilities
- Group funding centrally managed

Investment policy
- Security and liquidity
- Financial counterparty limits

Foreign Exchange Policy
- Foreign Exchange exposures managed centrally
- Transactional currency exposures substantially hedged

Interest Rate Policy
- Aim to broadly match level of floating rate debt to cash over time
- Significant portion of financial liabilities at fixed interest rates

Credit Risk
- Cash managed centrally
- Derivatives positions predominately cash collateralised